Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC

◆ TRIAL DATA

A phase Ib/IIa study of vactosertib combined with pembrolizumab in non-MSI-high metastatic colorectal cancer demonstrated a manageable safety profile, with secondary outcomes including objective response rate, progression-free survival, and overall survival. (Nature Communications)